Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer Journal Article

   


Authors: Alektiar, K. M.; Makker, V.; Abu-Rustum, N. R.; Soslow, R. A.; Chi, D. S.; Barakat, R. R.; Aghajanian, C. A.
Article Title: Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer
Abstract: Objective: To report a single institution experience in surgical stage I-II serous endometrial cancer using combined carboplatin/paclitaxel and intravaginal radiation (IVRT). Methods: Between 10/00 and 12/06, 25 stage I-II patients with serous endometrial cancer were treated at our institution with surgery, postoperative IVRT, and concurrent chemotherapy (CT). Results: The mean age was 67 years old (range, 53-80 years). Surgery consisted of hysterectomy (TAH/BSO, 64%, LAVH/BSO, 36%), peritoneal washing, omental biopsy, and pelvic lymph-node dissection (median 14 nodes). Para-aortic node sampling was done in 88% (median, 6). IVRT median dose was 21 Gy (range, 18-21 Gy, in 3 fractions) and concurrent CT consisted of carboplatin to AUC = 5 and taxol to 175 mg/m<sup>2</sup> given every 3 weeks for 6 cycles. CT was well tolerated with 22/25 (88%) receiving 6 cycles. Three patients received ≤ 5 cycles; 2 owing to physician preference (3 and 4 cycles) and 1 owing to toxicity (5 cycles). Only 1 patient (4%) had grade 3 toxicity (abscess). Grade 2 neurotoxicity was seen in 5 patients (20%). All patients finished their IVRT as scheduled, and there was no grade 3 toxicity. With a median follow-up of 30 months, the 5-year progression-free and overall survival rate was 88%. None of the patients developed vaginal recurrence. Conclusions: Based on this study, surgical staging followed by IVRT and carboplatin/paclitaxel is well tolerated and effective in stage I-II serous endometrial cancer. Confirmation of these results on a larger number of patients with longer follow-up is still needed. © 2008 Elsevier Inc. All rights reserved.
Keywords: adult; cancer survival; clinical article; aged; aged, 80 and over; middle aged; cancer surgery; clinical trial; constipation; drug tolerability; fatigue; cancer recurrence; cancer growth; drug dose reduction; side effect; paclitaxel; adjuvant therapy; cancer adjuvant therapy; cancer patient; cancer radiotherapy; radiation dose; chemotherapy, adjuvant; cancer staging; follow up; hysterectomy; paraaortic lymph node; endometrial neoplasms; neoplasm staging; endometrium cancer; lymph node excision; carboplatin; multiple cycle treatment; antineoplastic combined chemotherapy protocols; carboplatin paclitaxel; intravaginal rt; serous endometrial cancer; abdominal abscess; dehydration; myalgia; odor; ovariectomy; pelvis lymphadenectomy; peripheral neuropathy; peritoneal biopsy; peritoneum lavage; tinnitus; drug administration schedule; radiotherapy; vagina
Journal Title: Gynecologic Oncology
Volume: 112
Issue: 1
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2009-01-01
Start Page: 142
End Page: 145
Language: English
DOI: 10.1016/j.ygyno.2008.10.006
PUBMED: 19019418
PROVIDER: scopus
PMCID: PMC3763507
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-57649088307&partnerID=40&md5=6465a9b21c3f1ae58002cf16e028cb71
Notes: --- - "Cited By (since 1996): 2" - "Export Date: 30 November 2010" - "CODEN: GYNOA" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Vicky Makker
    263 Makker
  2. Richard R Barakat
    629 Barakat
  3. Dennis S Chi
    707 Chi
  4. Kaled M Alektiar
    333 Alektiar
  5. Nadeem Abu-Rustum
    888 Abu-Rustum
  6. Robert Soslow
    793 Soslow
  7. Carol A Aghajanian
    607 Aghajanian
Related MSK Work